A method of treatment of diarrhea-predominant IBS in a subject, comprising administering to a subject in need of treatment a therapeutically effective amount of a composition comprising cilansetron or a pharmaceutically acceptable derivative thereof; and providing information that indicates that constipation, abdominal pain, upper respiratory tract infection and/or nausea may occur after administering the composition.